Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
FASEB J ; 33(1): 1167-1178, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30113883

RESUMEN

The use of recombinant proteins has revolutionized the development of biologic pharmaceuticals; however, they are not free of complications. Some have very high molecular weight, some demonstrate in vivo instability, and the high cost of producing them remains a major problem. On the other hand, it has been shown that peptides derived from active domains keep their biologic activity and can trigger events, such as osteogenesis and bone regeneration. Small peptides are advantageous because of their ease of synthesis and handling and their low immunogenic activity. The purpose of this study was to investigate the functions of a synthetic peptide, cementum protein 1-peptide1 (CEMP-1-p1), both in vitro and in vivo. Our results show that CEMP-1-p1 significantly enhanced the proliferation and differentiation of human periodontal ligament cells toward a mineralizing-like phenotype, as evidenced by increasing alkaline phosphatase (ALP)-specific activity and osterix, runt-related transcription factor (RUNX)-2, integrin binding sialoprotein, bone morphogenetic protein-2, osteocalcin, and cementum protein (CEMP)-1 expression at mRNA and protein levels. In vivo assays performed through standardized critical-size calvarial defects in rats treated with CEMP-1-p1 resulted in newly formed bone after 30 and 60 d. These data demonstrate that CEMP-1-p1 is an effective bioactive peptide for bone tissue regeneration. The application of this bioactive peptide may lead to implementing new strategies for the regeneration of bone and other mineralized tissues.-Correa, R., Arenas, J., Montoya, G., Hoz, L., López, S., Salgado, F., Arroyo, R., Salmeron, N., Romo, E., Zeichner-David, M., Arzate, H. Synthetic cementum protein 1-derived peptide regulates mineralization in vitro and promotes bone regeneration in vivo.


Asunto(s)
Regeneración Ósea/fisiología , Calcificación Fisiológica/fisiología , Péptidos/farmacología , Proteínas/fisiología , Animales , Biomarcadores/metabolismo , Diferenciación Celular/fisiología , Proliferación Celular/fisiología , Células Cultivadas , Humanos , Masculino , Modelos Animales , Ligamento Periodontal/citología , Ligamento Periodontal/metabolismo , Proteínas/química , Ratas , Ratas Wistar , Cráneo/anomalías
2.
Environ Microbiol ; 16(5): 1282-96, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24447641

RESUMEN

To analyse whether the mutation-driven resistance-acquisition potential of a given bacterium might be a function of its intrinsic resistome, quinolones were used as selective agents and Stenotrophomonas maltophilia was chosen as a bacterial model. S. maltophilia has two elements - SmQnr and SmeDEF - that are important in intrinsic resistance to quinolones. Using a battery of mutants in which either or both of these elements had been removed, the apparent mutation frequency for quinolone resistance and the phenotype of the selected mutants were found to be related to the intrinsic resistome and also depended on the concentration of the selector. Most mutants had phenotypes compatible with the overexpression of multidrug efflux pump(s); SmeDEF overexpression was the most common cause of quinolone resistance. Whole genome sequencing showed that mutations of the SmeRv regulator, which result in the overexpression of the efflux pump SmeVWX, are the cause of quinolone resistance in mutants not overexpressing SmeDEF. These results indicate that the development of mutation-driven antibiotic resistance is highly dependent on the intrinsic resistome, which, at least for synthetic antibiotics such as quinolones, did not develop as a response to the presence of antibiotics in the natural ecosystems in which S. maltophilia evolved.


Asunto(s)
Antibacterianos/farmacología , Quinolonas/farmacología , Stenotrophomonas maltophilia/efectos de los fármacos , Proteínas Bacterianas/metabolismo , Farmacorresistencia Bacteriana/genética , Proteínas de Transporte de Membrana/metabolismo , Mutación , Stenotrophomonas maltophilia/genética , Stenotrophomonas maltophilia/metabolismo
3.
Artículo en Inglés | MEDLINE | ID: mdl-38849115

RESUMEN

INTRODUCTION: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a serious threat to public health. Globally, carbapenemases-producing CRPA isolates mainly belong to 'high-risk' clones; however, the molecular epidemiology of CRPA isolates circulating in Chile are scarce, where this pathogen is the main aetiological agent of ventilator-associated pneumonia. OBJECTIVES: To characterize the phylogenomics and molecular features of ST654 CRPA isolates collected in Chile between 2016 - 2022. METHODS: 89 CRPA isolates collected in different Chilean hospitals from clinical specimens between 2005 and 2022 were analyzed. Antibiotic susceptibility tests and carbapenemases production were carried out on the CRPA ST654 isolates. Also, they were subjected to whole-genome sequencing (WGS) from which in silico analyses were performed. RESULTS: Thirty-four strains (38.2%) belonged to the ST654 'high risk' clone, being the most predominant lineage of the collection. Most of these isolates belonged to a sub-clade including KPC-producers that also clustered with strains from Argentina and the USA, whereas few VIM and NDM co-producers clustered in two different smaller sub-clades. The isolates exhibited a broad resistome encompassing genes mediating resistance to several other clinically relevant drugs. Additionally, all the 34 ST654 isolates were ExoS+ as a virulence factor and associated to the O4-serotype. CONCLUSIONS: Our report represents the most comprehensive phylogenomic study of CRPA 'high risk' clone ST654 to date. Our analyses suggest that this lineage is undergoing a divergent evolutionary path in Chile, since most of the isolates were KPC-producers and were O4-serotype, differing from previous descriptions, which underline the relevance of performing molecular surveillance on this pathogen.

4.
Biomed Res Int ; 2019: 5070453, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31312657

RESUMEN

BACKGROUND: Obesity and pregnancy increase levels of maternal oxidative stress (OS). However, little is known about the maternal, placental, and neonatal OS status. OBJECTIVE: To analyze the relation between prepregnancy obesity and the expression of OS markers and antioxidant capacity in the fetomaternal unit and their association with dietary intake. METHODS: This cross-sectional study included 33 women with singleton, noncomplicated pregnancies. Two groups were formed: women with prepregnancy body mass index (pBMI) within normal range (18.5-24.9 kg/m2, n = 18) and women with pBMI ≥ 30 kg/m2, suggestive of obesity (n = 15). Dietary and clinical information was obtained by questionnaire and from clinical records. Total antioxidant capacity (TAC) and malondialdehyde (MDA) concentration were measured on maternal and cord serum by colorimetric techniques, and placental expression of glutathione peroxidase 4 (GPx4) was measured by immunohistochemistry. RESULTS: Placental GPx4 expression was lower in the group with pBMI suggestive of obesity than in the normal weight group (ß = -0.08, p = 0.03, adjusted for gestational age and magnesium intake). Concentrations of TAC and MDA in maternal and cord blood were not statistically different between groups (p>0.05). Cord MDA concentration was related to maternal MDA concentration (ß = 0.40, p < 0.01), vitamin A intake (tertile 2: ß = -0.04, p = 0.40, tertile 3: ß = 0.13, p = 0.03, vs tertile 1), and placental GPx4 expression (ß = -0.09, p = 0.02). CONCLUSION: Prepregnancy obesity is associated with a decrease in GPx4 expression in the placenta, which is related to OS in the newborn. The influence of micronutrient intake on OS biomarkers highlights the importance of nutritional assessment during pregnancy and adequate prenatal care.


Asunto(s)
Micronutrientes/sangre , Obesidad Materna/dietoterapia , Estrés Oxidativo/genética , Fosfolípido Hidroperóxido Glutatión Peroxidasa/sangre , Adulto , Antioxidantes/metabolismo , Índice de Masa Corporal , Ingestión de Alimentos/fisiología , Femenino , Regulación Enzimológica de la Expresión Génica , Humanos , Malondialdehído/sangre , Relaciones Materno-Fetales/fisiología , Madres , Evaluación Nutricional , Obesidad Materna/sangre , Obesidad Materna/fisiopatología , Placenta/metabolismo , Embarazo , Vitamina A/sangre
5.
Odontol.sanmarquina (Impr.) ; 26(4): e24819, oct.-dic. 2023.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1551415

RESUMEN

El queratoquiste odontogénico es una lesión intraósea, que surge de restos de la lámina dental y células basales de la mucosa que lo recubre. Ocurre con mayor frecuencia entre la segunda y tercera década de vida, con una incidencia entre el 5 al 14% de todos los quistes odontogénicos; su recidiva varía según el tratamiento, llegando a ser del 23% solo con la enucleación. El objetivo de este artículo es reportar dos casos de queratoquiste con diferentes terapias de tratamiento en queratoquistes recidivantes (marsupialización, descompresión y uso del 5-fluororuracilo); divulgamos este informe debido a la importancia de tratamientos no invasivos con terapias adyuvantes que disminuyen la recidiva en pacientes con queratoquiste.


The odontogenic keratocyst is an intraosseous lesion that arises from remains of the dental lamina and basal cells of the overlying mucosa. It occurs most frequently between the second and third decade of life, with an incidence between 5 to 14% of all odontogenic cysts; its recurrence varies according to the treatment, reaching 23% only with enucleation. The aim of this article is to report two cases of keratocyst with different treatment therapies in recurrent keratocyst (marsupialization, decompression and use of 5-fluoruracil); we disclose this report due to the importance of non-invasive treatments with adjuvant therapies that reduce recurrence in patients with keratocyst.

6.
Birth Defects Res ; 110(16): 1223-1227, 2018 10 02.
Artículo en Inglés | MEDLINE | ID: mdl-30063111

RESUMEN

BACKGROUND: Folate plays a fundamental role for fetal development, participating in cell division, embryogenesis, and fetal growth. The fetus depends on maternal supply of folate across the placenta. The objective of this study was to compare the expression of Folate Receptor-α (FR-α), Reduced Folate Carrier (RFC), and Proton Coupled Folate Transporter (PCFT) in placentas from pregnancies complicated with birth defects (BD) and controls. METHODS: Case-control study, including placentas of BD-complicated pregnancies (n = 25) and a control group (n = 25). We determined the placental expression of FR-α, RFC, and PCFT by immunohistochemistry. Optical density was measured to obtain a relative quantification of the expression. RESULTS: The expression of PCFT was greater in placentas from pregnancies complicated with BD than in those from the control group (p < .01). The expression of FR-α and RFC was not different between groups. CONCLUSION: The expression of PCFT in placentas from BD-complicated pregnancies is increased, possibly as an adaptive response to increase the folate flux at the maternal-fetal interface.


Asunto(s)
Transportadores de Ácido Fólico/genética , Ácido Fólico/metabolismo , Placenta/metabolismo , Adulto , Estudios de Casos y Controles , Anomalías Congénitas/fisiopatología , Femenino , Receptor 1 de Folato/análisis , Receptor 1 de Folato/metabolismo , Transportadores de Ácido Fólico/metabolismo , Humanos , Inmunohistoquímica , Embarazo , Complicaciones del Embarazo , Transportador de Folato Acoplado a Protón/análisis , Transportador de Folato Acoplado a Protón/metabolismo , Proteína Portadora de Folato Reducido/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA